<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166403">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01789398</url>
  </required_header>
  <id_info>
    <org_study_id>P10-01 / BF2.649</org_study_id>
    <secondary_id>2011-000084-27</secondary_id>
    <nct_id>NCT01789398</nct_id>
  </id_info>
  <brief_title>Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV)</brief_title>
  <acronym>HARMONY IV</acronym>
  <official_title>Double Blind Randomized Study to Assess the Efficacy of BF2.649 Compared to Placebo in add-on to Sodium Oxybate in the Treatment of Narcoleptic Patients With Residual Excessive Daytime Sleepiness (EDS) During 8 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioprojet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioprojet</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentric international phase III, double blind randomized study assessing
      efficacy and safety in parallel group of BF2.649 (pitolisant) compared to placebo in add-on
      to sodium oxybate of narcoleptic patients with residual Excessive Daytime Sleepiness (EDS)
      during 8 weeks
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy on EDS as measured by ESS ( Epworth Sleepiness Scale)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on the ESS score change from baseline to final visit.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Narcolepsy</condition>
  <arm_group>
    <arm_group_label>BF2.649 (pitolisant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo of BF2.649 (5mg, 10mg, 20mg or 40mg) in capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of BF2.649 (5mg, 10mg, 20mg or 40mg) in capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BF2.649</intervention_name>
    <description>BF2.649 is provided in capsules. Patients should take 1 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast).</description>
    <arm_group_label>BF2.649 (pitolisant)</arm_group_label>
    <other_name>pitolisant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females, aged 18 years old and over.

          -  Patients with a diagnosis of narcolepsy according to the International Classification
             of Sleep Disorders (ICSD-2) criteria

          -  Patients treated with sodium oxybate (Xyrem®) with a stable dosage for at least 2
             months prior to the trial.

          -  Patients complaining of residual EDS

          -  Patient should be free of non authorized drugs or discontinue any psychostimulant
             medication at least 3 weeks before randomization (V2).

          -  Females of child-bearing potential must use a medically accepted effective method of
             birth control, agree to continue this method for the duration of the study and be
             negative to serum pregnancy test performed at the screening visit. Females should not
             be breast-feeding patient.

          -  In the opinion of the investigator, the patient must have adequate support to comply
             with the entire study requirements as described in the protocol (e.g. transportation
             to and from trial site, self rating scales, drug compliance, scheduled visits, etc).

          -  Patient must have voluntarily expressed a willingness to participate in this study,
             signed and dated an informed consent prior to beginning this protocol required
             procedures.

        Exclusion Criteria:

          -  Psychiatric and neurological disorders, other than narcolepsy/cataplexy, such as
             moderate or severe psychosis or dementia, bipolar illness, severe anxiety, clinical
             severe depression (BDI ≥ 16) with suicidal risk (item G BDI &gt; 0), or depression
             treated for less than 8 weeks, history of seizure disorder or other problem that in
             the investigator's opinion would preclude the patient's participation and completion
             of this trial or comprise reliable representation of subjective symptoms.

          -  Patients working in an occupation requiring variable shift work or routine night
             shifts.

          -  Patients with an untreated sleep apnea disorder (defined as an apnea index &gt; 10/h or
             an apnea/hypopnea index&gt;15/h) or who have any other cause of daytime sleepiness.

          -  Use of hypnotics, tranquilizers, sedating antihistamines, psychostimulants for the
             treatment of EDS (amphetamine and amphetamine-like CNS stimulants, modafinil,
             methylphenidate or others), benzodiazepines, anticonvulsants or clonidine will not be
             accepted at least 3 weeks before randomization (V2) and during study.

          -  Current or recent (within one year) history of a substance abuse or dependence
             disorder including alcohol abuse as defined in Diagnostic and Statistical Manual of
             Mental Disorders (DSM-IV).

          -  Other active clinically significant illness, including unstable cardiovascular, or
             neoplasic pathology which could interfere with the study conduct or counter-indicate
             the study treatments or place the patient at risk during the trial or compromise the
             study participation.

          -  Patient with a known history of long QTc syndrome (e.g. syncope or arythmia) or
             presenting any significant serious abnormality of the ECG (e.g. recent myocardial
             infarction), or QTc interval strictly higher than 450 ms (electrocardiogram Bazett's
             corrected).

          -  Patients with Severe Hepatic Impairment or with Severe Renal Impairment, or with any
             other significant abnormality in the physical examination or clinical laboratory
             results.

          -  Known hypersensitivity to the tested treatment including active substance and
             excipients.

          -  Patients participating in an other study and the use of any investigational therapy
             within the 30 days prior to the entry in this study.

          -  Patient without any medical care insurance
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves DAUVILLIERS</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Gui de Chauliac - 80, avenue A. Fliche , 34295 Montpellier cedex 5 - FRANCE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle Lecomte, M.D.</last_name>
    <phone>0033 (0)1 47 03 66 33</phone>
    <email>i.lecomte@bioprojet.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Dauvilliers, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yves Dauvilliers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>February 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Narcolepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sodium Oxybate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
